Beam Therapeutics Leads in Genetic Editing for Alpha-1 Antitrypsin Deficiency
Beam Therapeutics and Wave Life Sciences have both reported promising results in the treatment of alpha-1 antitrypsin deficiency (AATD) using genetic editing technologies. Beam's DNA editor, BEAM-302, demonstrated significant efficacy by reducing levels of the mutated AAT protein and increasing the production of the healthy version. This was achieved with a single dose, showing durable effects over 12 months. Wave's RNA editor, WVE-006, also showed efficacy but was considered less effective compared to Beam's approach. Analysts suggest Beam's technology may have a first-mover advantage in the market. 
